The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

NCT03236649 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

89

Enrollment

INDUSTRY

Sponsor class

Stopped Because the clinical development plan has been changed.

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Icaritin
DRUG: Sorafenib Tosylate Tablets

Sponsor

Beijing Shenogen Biomedical Co., Ltd

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]